Dutch biotech SME delivering constrained peptide design and synthesis for therapeutic, diagnostic, and biomaterial research consortia.
Pepscan Therapeutics is a Dutch biotech SME based in Lelystad specializing in peptide chemistry, peptide synthesis, and peptide-based drug discovery. The company is best known for its proprietary CLIPS technology (Chemical Linkage of Peptides onto Scaffolds), which locks peptides into defined three-dimensional conformations to dramatically improve their potency and stability as therapeutic or diagnostic agents. In H2020, Pepscan contributed its peptide engineering expertise to two research consortia: one developing biomimetic hydrogels for biomedical applications (BIOGEL) and one investigating thyroid hormone modulation to prevent age-related diseases (THYRAGE). They function as a specialist industry partner, providing peptide design, synthesis, and characterization capabilities that academic groups typically cannot deliver in-house.
Pepscan's core commercial offering — constrained peptide scaffolds — underpins their contributions to both BIOGEL (functional peptide sequences for hydrogel assembly) and THYRAGE (peptide-based tools for thyroid axis research).
BIOGEL (2015–2018) directly involved engineering responsive, biomimetic hydrogels for therapeutic and diagnostic applications, a field where peptide sequences drive gel formation and bioactivity.
THYRAGE (2016–2021) targeted thyroid axis modulation as a strategy for preventing age-related co-morbidities, with Pepscan contributing peptide tools to a EUR 601,875 research effort.
BIOGEL's diagnostic application dimension and Pepscan's commercial PEPSCREEN library services suggest diagnostics as a secondary but growing application area.
Pepscan's two H2020 projects both launched in 2015–2016, making a genuine timeline evolution difficult to establish from EU project data alone. What the project sequence does suggest is a trajectory from biomaterials research (BIOGEL, 2015–2018, classified under Research Excellence) toward biomedical therapeutics with a clinical horizon (THYRAGE, 2016–2021, classified under Health), reflecting a shift from enabling-technology research to disease-focused application. No later H2020 projects are recorded, so it is unclear whether this direction continued into Horizon Europe or whether the company shifted focus after 2021.
Based on the available H2020 data, Pepscan appears to be moving from fundamental biomaterials research toward disease-targeted therapeutic peptide applications, particularly in endocrinology and aging — a direction that aligns with growing industry demand for peptide drugs.
Pepscan has participated exclusively as a consortium partner in both recorded H2020 projects, never taking on a coordinator role — a pattern consistent with a specialist SME that contributes a defined technical capability rather than managing large research agendas. With 19 unique partners across 13 countries from just two projects, they operate in standard-sized European consortia and show a broad collaborative footprint rather than a tight circle of repeat partners. Working with Pepscan likely means accessing a focused peptide chemistry service embedded within a larger academic-led consortium.
Pepscan has built connections with 19 unique consortium partners across 13 countries through two projects, suggesting they engage in well-structured, multi-national consortia rather than bilateral partnerships. No clear geographic concentration is visible from the data, indicating a genuinely pan-European collaboration profile.
Pepscan sits at a rare intersection: an SME with deep proprietary technology (CLIPS constrained peptide platform) that is commercially mature enough to serve pharma clients yet research-active enough to contribute to EU academic consortia. Most peptide chemistry players are either pure CROs (contract research only) or pure academics — Pepscan bridges both worlds. For consortium builders, this means access to industrial-grade peptide synthesis and characterization within a research partnership framework, without the overhead of engaging a large pharmaceutical company.
